Aligos Therapeutics Provides Important Business Update
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical stage biotechnology firm dedicated to enhancing patient care through innovative therapies targeting liver and viral diseases, has shared significant developments in its business trajectory and the financial outcome for the second quarter of 2025.
Advancements in Clinical Trials
According to Lawrence Blatt, Ph.D., M.B.A., the Chairman, President, and CEO of Aligos Therapeutics, the Phase 2 B-SUPREME study of ALG-000184 is making steady progress. The study has received approvals from various regulatory authorities worldwide, including the US and several countries across Asia and Europe. Active site setups are ongoing, and participant screening is underway, with the goal of starting dosing shortly.
Focus on Hepatitis B Treatment
The B-SUPREME study aims to evaluate the safety and efficacy of ALG-000184. This randomized, controlled trial involves approximately 200 participants suffering from chronic hepatitis B virus (HBV) infection. The primary goal is to determine the levels of HBV DNA suppression, with results expected to be released in the subsequent years.
Positive Phase 1 Data
Results presented at the European Association for the Study of the Liver Congress indicated promising outcomes from a 96-week Phase 1 trial. ALG-000184 demonstrated excellent tolerance and significant antiviral activity, raising hopes for it to potentially become the standard treatment for chronic HBV infection. These results highlight the need for innovative therapies that could lead to functional cures for HBV.
Innovative Pipeline Initiatives
Beyond ALG-000184, Aligos has been focusing on other candidates in its pipeline that address various therapeutic needs.
ALG-055009: Targeting Metabolic Disorders
ALG-055009 is a small molecule THR-? agonist designed for treating metabolic dysfunction-associated steatohepatitis (MASH). Recent data indicates that this compound has successfully met primary endpoints in clinical trials, showing statistically significant liver fat reduction. Notably, this therapeutic has also illustrated reductions in atherogenic lipid levels, which could benefit patients facing cardiovascular risk factors.
ALG-097558: Tackling COVID-19
The development of ALG-097558, a pan-coronavirus protease inhibitor, continues to progress. It is currently under investigation through the AGILE platform study, which examines its efficacy alone or in combination with other treatments in high-risk COVID-19 subjects. Aligos anticipates that external funding could support future developments for this promising compound.
Financial Overview for Q2 2025
Aligos reported a cash position of $122.9 million at the quarter's close, marking a significant increase from the previous year. This financial backing is projected to effectively fund ongoing operational needs into the latter half of 2026, showcasing the company’s stability despite operational losses.
Understanding the Net Loss
The net loss for the quarter ended June 30, 2025, was reported at $15.9 million. This contrasts with a profit during the same period last year. Decreased R&D expenditures contributed to this loss, juxtaposed with escalating costs related to chronic HBV initiatives.
Operational Costs
The R&D expenses totaled $14.0 million, a notable decrease from the previous year's $21.1 million, due to reduced third-party expenses following the completion of certain trials. Administrative expenses similarly showed a decline owing to cuts in legal and operational costs, representing prudent management of resources.
About Aligos Therapeutics
Aligos Therapeutics, Inc., listed on NASDAQ under the ticker ALGS, strives to create leading therapies targeting unmet medical needs in liver and viral diseases. By leveraging its dedicated R&D capabilities, the company aims to transform the treatment landscape for chronic hepatitis B virus and other health concerns associated with metabolic dysfunction and viral pandemics.
Frequently Asked Questions
What is the recent progress made by Aligos Therapeutics?
Aligos has reported that the Phase 2 B-SUPREME study for ALG-000184 is advancing well with regulatory approvals and patient screening activities ongoing.
What are the key therapeutic focuses of Aligos Therapeutics?
The company focuses on developing treatments for diseases such as chronic hepatitis B, metabolic disorders, and coronaviruses.
How did Aligos' financial performance look in Q2 2025?
Aligos recorded a cash position of $122.9 million, alongside a net loss of $15.9 million for the quarter.
What is ALG-000184's significance in the treatment of HBV?
Data suggests that ALG-000184 could replace current standard treatments for chronic HBV, potentially leading to functional cures for patients.
How is Aligos planning to fund its future developments?
The company is looking at various funding avenues, including possible out-licensing opportunities to ensure ongoing project developments and operational funding.
